In the prospective, adding cancer marker CA-62 alone or in a panel TM signature (CA-62, CEA and CYFRA 21-1) to the existing LC risk assessment system as a pre-screening tool for LDCT-scan may improve the quality of early-stage lung cancer detection by significantly increasing the sensitivity and by reducing the proportion of false positive results. Here, CEACAM5 is linked to lung cancer.